FDA Clears New Trials of Platelet-Derived Growth Factor Injections for Facial Aesthetics

Key Takeaways

  • The FDA has authorized 2 investigational new drug (IND) applications for investigator-initiated trials evaluating injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in facial aesthetics.
  • The studies will examine cellular changes in facial skin and the safety and efficacy of rhPDGF-BB injections for infraorbital hollowing, enrolling 12 and 30 participants, respectively.
  • Both studies are expected to conclude in 2027. Injectable rhPDGF-BB remains investigational for these aesthetic indications and is not FDA-approved.
11/18/2026
Lynch regen med

Lynch Regenerative Medicine (LRM) announced that the US Food and Drug Administration (FDA) has authorized two investigational new drug (IND) applications for investigator-initiated clinical trials evaluating injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) for facial skin quality and infraorbital hollowing.

The studies will investigate the biological effects of rhPDGF-BB in facial skin and its potential safety and efficacy as an injectable treatment for under-eye hollowing, according to a company press release issued November 18, 2026.

Clinical Trials to Evaluate Facial Skin Regeneration and Infraorbital Hollowing

The first study, led by facial plastic surgeon Michael Somenek, MD, will enroll 12 participants to investigate cellular responses to rhPDGF-BB injections in facial skin. Researchers will obtain skin biopsies at 7, 14, or 28 days, or 8 weeks after treatment, assessing changes in gene and protein expression associated with collagen, elastin, and other extracellular matrix components. Completion is anticipated in the second quarter of 2027.

A second trial, led by Sarah Allen, MD, founder and chief medical officer of Skin Clique, will enroll 30 participants to evaluate injectable rhPDGF-BB for infraorbital hollowing. Investigators will assess safety and changes in tear trough appearance, dark shadows, skin thickness, smoothness, and brightness at 12 weeks following injection. Completion is expected in the third quarter of 2027.

The new studies follow a separate FDA IND authorization for a Phase IIb trial evaluating injectable rhPDGF-BB for infraorbital hollowing.

The company has not reported efficacy or safety results from the newly authorized trials. The injectable aesthetic applications remain investigational and are not FDA-approved.

"Platelet-derived growth factor is not new to medicine. Our colleagues in orthopedics, oral and maxillofacial surgery, and wound care have used rhPDGF-BB for decades, and that long record of clinical experience is what has given me the confidence to study it in aesthetics," said Sarah Allen, MD. "If we want to move aesthetic medicine forward safely, physicians and investigators must be part of the solution, and that means participating in structured clinical trials that put patient safety first. Infraorbital hollowing is one of the most common concerns patients bring to us, yet treatment options have changed very little in more than two decades. I am excited to participate in determining whether a regenerative approach has a place in treating this area."

Source

Lynch Regenerative Medicine, LLC. Lynch Regenerative Medicine (LRM) announces FDA authorization of two new INDs for investigator-initiated clinical trials evaluating injectable rhPDGF-BB for facial skin quality and treatment of infraorbital hollowing. PR Newswire. Published November 18, 2026. Accessed November 18, 2026. Original press release.

Register

We're glad to see you're enjoying ModernAesthetics…
but how about a more personalized experience?

Register for free